Follistatin-344 Side Effects: What Gene-Therapy Trials Show and What Is Still Theoretical

There are no published human trials of follistatin-344 given as a finished protein or "peptide" product, so it has no established human side-effect profile. The closest human data come from small gene-therapy trials in Becker muscular dystrophy and inclusion body myositis, which reported no treatment-related adverse effects in six patients each. The main concerns are therefore mechanistic and animal-derived: follistatin binds activin as well as myostatin, and widespread follistatin overexpression in mice caused testicular, ovarian and fertility defects.

This guide sets out each reported or proposed adverse effect, the evidence it comes from, and the contraindication and monitoring questions a prescriber should work through.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

What Follistatin-344 Is

Follistatin is a secreted glycoprotein, not a short peptide. "FS344" names the 344-amino-acid precursor of one splice variant, which is processed into the circulating FS315 form. Follistatin was first characterized as a gonadal protein that suppresses pituitary release of follicle-stimulating hormone (FSH) [2]. Its interest for muscle comes from a later discovery: follistatin blocks myostatin, the TGF-beta family member that limits skeletal muscle mass, and mice engineered to express it in muscle showed dramatic muscle growth [1]. For the broader background, see the Follistatin-344 library page and our article on follistatin-344, myostatin and hair growth.

The same binding that makes follistatin a myostatin antagonist also makes it an activin antagonist, and activin regulates FSH and gonadal function. That overlap drives most of the safety discussion.

Follistatin-344 Side Effects: Evidence Table

What the Human Gene-Therapy Trials Showed

The only human follistatin exposure in the peer-reviewed literature is from gene therapy, in which an adeno-associated virus vector carrying the FS344 gene was delivered directly into the quadriceps.

• Becker muscular dystrophy (phase 1/2a). Six patients were treated in two cohorts. Four of the six improved their six-minute walk distance, and "no adverse effects were encountered." Biopsies showed reduced fibrosis and muscle fiber hypertrophy [5].
• Sporadic inclusion body myositis. Six patients were treated and compared with eight untreated matched controls. Four of six showed meaningful walk-test gains; the abstract does not report safety signals [7].

The investigators chose the FS344 variant deliberately. Its processed form, FS315, circulates in serum and has roughly tenfold lower affinity for activin than the tissue-bound FS288 form, and the team cited the risk of suppressing pituitary FSH as the reason for caution [6].

These findings do not transfer cleanly to a compounded or research-grade protein. Gene therapy produces sustained local expression inside muscle; an externally supplied protein produces systemic exposure whose distribution, half-life and activin-binding profile have not been characterized in humans. The absence of adverse effects in twelve gene-therapy patients is not evidence that a commercial follistatin product is safe.

The Activin and FSH Question

Follistatin was named for its ability to suppress FSH [2]. In mice engineered to overexpress follistatin, the consequences were concentrated in the gonads: variable testicular atrophy, Leydig cell hyperplasia, arrested spermatogenesis, thin uteri, blocked folliculogenesis and infertility in the most affected lines [3]. Serum FSH was suppressed only in the line with the most widespread expression, which the authors read as evidence that follistatin acts locally in the gonads as well as at the pituitary.

For a prescriber, the practical point is that reproductive-axis effects are the most biologically plausible adverse effect in humans, even though none has been documented.

The Class Signal From Other Myostatin Blockers

ACE-031, a decoy activin type IIB receptor that binds myostatin and related ligands, was tested in boys with Duchenne muscular dystrophy. It produced no serious adverse events, but the trial was stopped over epistaxis and telangiectasias, which the authors described as non-muscle-related adverse events [8]. ACE-031 is not follistatin, and the mechanism of those vascular findings may differ. The lesson is that blocking the myostatin/activin family affects tissues other than muscle, and that off-target effects surfaced only once a randomized human trial was run.

Who Should Avoid Follistatin-344

Based on the mechanism and animal data, the following groups carry the clearest theoretical risk:

• Pregnancy, breastfeeding, or trying to conceive. Activin and follistatin signaling is central to reproductive physiology, and overexpression impaired fertility in both sexes in mice [3].

• Patients concerned about fertility, including men with existing low sperm counts or hypogonadism.
• Children and adolescents, whose reproductive axis and growth are still developing.
• Active or prior hormone-sensitive malignancy. The activin/follistatin network is studied in breast development and cancer [9]; there are no human data to rule out an effect.
• Competitive athletes. Non-approved substances fall within WADA's prohibited categories.

Monitoring Considerations for Prescribers

There is no validated monitoring scheme, because there is no human safety program for this product. Considerations that follow from the mechanism:

• Reproductive hormones at baseline and during use: FSH, LH, and testosterone or estradiol as appropriate, plus menstrual history in women.
• Semen analysis for men who want to preserve fertility.
• Bleeding history, including new nosebleeds or visible skin vessel changes, given the class signal from ACE-031 [8].
• Source documentation: identity, purity and endotoxin testing from the dispensing pharmacy.

Any new symptom should prompt stopping and reassessment rather than continued use.

Regulatory Status (October 2026)

Follistatin-344 is not an FDA-approved drug and is not on the 503A Bulks List. It is not among the substances our FDA Peptide Status Tracker lists as under evaluation or scheduled for a PCAC meeting. Confirm current compounding eligibility with the partner pharmacy before prescribing.

Frequently Asked Questions

What are the side effects of follistatin-344?

No human side-effect profile exists, because the product itself has not been tested in published human trials. Small gene-therapy trials reported no treatment-related adverse effects. The main theoretical concerns, drawn from mouse studies and the protein's activin binding, are reduced FSH and impaired fertility.

Can follistatin-344 affect fertility?

It is the most plausible risk. Follistatin was discovered as an FSH-suppressing protein, and mice overexpressing it had small testes, arrested sperm production, small ovaries and infertility. Human data do not exist either way.

Is follistatin gene therapy the same as follistatin-344 peptide?

No. Gene therapy delivers the FS344 gene so muscle cells make the protein locally over a long period. A supplied protein creates systemic exposure with an uncharacterized profile, so gene-therapy safety findings cannot be assumed to apply.

Does follistatin-344 cause hair loss or hair growth?

Transgenic mice overexpressing follistatin had altered, shiny and irregular fur. Human hair effects have not been studied in controlled trials; see our follistatin-344 hair growth article for what has been proposed.

Is follistatin-344 FDA approved?

No. It is not FDA-approved and is not on the 503A Bulks List. Check the FDA Peptide Status Tracker and confirm with the compounding partner before prescribing.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A compounding partners; prescribers can start at For Providers. For the wider context on muscle-focused compounds, see our peptides for muscle growth guide.

References

1. Lee SJ, et al. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001;98(16):9306-11. PubMed
2. Esch FS, et al. Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol. 1987;1(11):849-55. PubMed
3. Guo Q, et al. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol. 1998;12(1):96-106. PubMed
4. Kota J, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15. PubMed
5. Mendell JR, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23(1):192-201. PubMed
6. Al-Zaidy SA, et al. Follistatin gene therapy improves ambulation in Becker muscular dystrophy. J Neuromuscul Dis. 2015;2(3):185-192. PubMed
7. Mendell JR, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25(4):870-879. PubMed
8. Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458-464. PubMed
9. Seachrist DD, et al. The activin social network: activin, inhibin, and follistatin in breast development and cancer. Endocrinology. 2019;160(5):1097-1110. PubMed